Published in Int J Rheum Dis on April 04, 2013
Osteoarthritis: an overview of the disease and its treatment strategies. Semin Arthritis Rheum (2005) 2.39
Identification of the clinical features distinguishing psoriatic arthritis and fibromyalgia. J Rheumatol (2012) 2.18
Early psoriatic arthritis: the clinical spectrum. J Rheumatol (2007) 1.79
Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. J Rheumatol (2011) 1.52
Platelet reactivity and disease activity in subjects with psoriatic arthritis. J Rheumatol (2011) 1.51
Serum amyloid-A in Behçet's disease. Clin Rheumatol (2014) 1.47
Is the Nail Psoriasis Severity Index reliable in the assessment of nail psoriasis by rheumatologists? Arthritis Care Res (Hoboken) (2012) 1.46
Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance. J Clin Endocrinol Metab (2007) 1.43
Psoriasis, psoriatic arthritis, or psoriatic disease? J Rheumatol (2006) 1.19
The effectiveness and safety of TNF-alpha blockers in the treatment of early psoriatic arthritis: an Italian multicentre longitudinal observational pilot study. Clin Rheumatol (2011) 1.15
Fat-free mass and fat mass reference values by dual-energy X-ray absorptiometry (DEXA) in a 20-80 year-old Italian population. Clin Nutr (2008) 1.07
Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers. Ann Rheum Dis (2013) 1.07
Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis. Arthritis Care Res (Hoboken) (2013) 1.05
Overlap connective tissue disease syndromes. Autoimmun Rev (2012) 1.05
Carotid intima-media thickness in psoriatic arthritis: differences between tumor necrosis factor-α blockers and traditional disease-modifying antirheumatic drugs. Arterioscler Thromb Vasc Biol (2011) 1.02
Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study. Clin Rheumatol (2011) 1.02
Nail and distal interphalangeal joint in psoriatic arthritis. J Rheumatol (2006) 1.00
Blau syndrome, clinical and genetic aspects. Autoimmun Rev (2012) 0.99
The potential role of bone scintigraphy in the detection of deep muscular fascia involvement and calcinosis cutis in anti-synthetase syndrome. Int J Rheum Dis (2013) 0.98
Prevalence of sarcopenia based on different diagnostic criteria using DEXA and appendicular skeletal muscle mass reference values in an Italian population aged 20 to 80. J Am Med Dir Assoc (2013) 0.98
Predictors of early minimal disease activity in patients with psoriatic arthritis treated with tumor necrosis factor-α blockers. J Rheumatol (2012) 0.98
Comorbid conditions in the AMICA study patients: effects on the quality of life and drug prescriptions by general practitioners and specialists. Semin Arthritis Rheum (2005) 0.97
Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. Clin Rheumatol (2010) 0.97
Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clin Rheumatol (2014) 0.94
Long-term safety of anti-TNF-α in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients. Clin Rheumatol (2013) 0.94
Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Behçet's disease: a case series. Dermatology (2014) 0.94
The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6-month trial with methotrexate. Clin Rheumatol (2007) 0.94
Biological treatments: new weapons in the management of monogenic autoinflammatory disorders. Mediators Inflamm (2013) 0.93
The labyrinth of autoinflammatory disorders: a snapshot on the activity of a third-level center in Italy. Clin Rheumatol (2014) 0.93
Anakinra treatment in drug-resistant Behcet's disease: a case series. Clin Rheumatol (2013) 0.92
Clinical presentation of osteoarthritis in general practice: determinants of pain in Italian patients in the AMICA study. Semin Arthritis Rheum (2005) 0.92
Long-lasting bone damage detected by dual-energy x-ray absorptiometry, phalangeal osteosonogrammetry, and in vitro growth of marrow stromal cells after allogeneic stem cell transplantation. J Clin Endocrinol Metab (2002) 0.92
Hepatic steatosis and disease activity in subjects with psoriatic arthritis receiving tumor necrosis factor-α blockers. J Rheumatol (2012) 0.91
Key facts and hot spots on tumor necrosis factor receptor-associated periodic syndrome. Clin Rheumatol (2014) 0.91
Monogenic autoinflammatory syndromes: state of the art on genetic, clinical, and therapeutic issues. Int J Rheumatol (2013) 0.91
New developments in magnetic resonance imaging of the nail unit. J Rheumatol Suppl (2012) 0.91
Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for Rheumatology. Clin Exp Rheumatol (2011) 0.90
Hepatic steatosis, carotid plaques and achieving MDA in psoriatic arthritis patients starting TNF-α blockers treatment: a prospective study. Arthritis Res Ther (2012) 0.90
Reduced bone mass detected by bone quantitative ultrasonometry and DEXA in pre- and postmenopausal women with endogenous subclinical hyperthyroidism. Maturitas (2004) 0.89
Distribution of HLA-B27 subtypes in Sardinia and continental Italy and their association with spondylarthropathies. Arthritis Rheum (2005) 0.89
The use of TNF-α blockers in psoriatic arthritis patients with latent tuberculosis infection. Clin Rheumatol (2014) 0.87
Enteropathic spondyloarthritis: from diagnosis to treatment. Clin Dev Immunol (2013) 0.87
Do physicians treat symptomatic osteoarthritis patients properly? Results of the AMICA experience. Semin Arthritis Rheum (2005) 0.87
Dynamic contrast-enhanced magnetic resonance imaging of articular and extraarticular synovial structures of the hands in patients with psoriatic arthritis. J Rheumatol Suppl (2012) 0.87
Cardiovascular risk in rheumatic patients: the link between inflammation and atherothrombosis. Semin Thromb Hemost (2012) 0.86
Screening and monitoring of latent tubercular infection in patients taking tumor necrosis factor-α blockers for psoriatic arthritis. J Rheumatol Suppl (2012) 0.86
Prevention of tuberculosis in patients taking tumor necrosis factor-alpha blockers. J Rheumatol Suppl (2009) 0.86
Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study. Rheumatology (Oxford) (2010) 0.85
Osteoporosis and psoriatic arthritis. J Rheumatol Suppl (2012) 0.84
Determinants and effects of vitamin D supplementation on serum 25-hydroxy-vitamin D levels in patients with rheumatoid arthritis. Clin Exp Rheumatol (2012) 0.83
JAK/STAT/PKCδ molecular pathways in synovial fluid T lymphocytes reflect the in vivo T helper-17 expansion in psoriatic arthritis. Immunol Res (2014) 0.83
Weekly oral alendronate in mevalonate kinase deficiency. Orphanet J Rare Dis (2013) 0.83
Psychometric properties of an index of three patient reported outcome (PRO) measures, termed the CLinical ARthritis Activity (PRO-CLARA) in patients with rheumatoid arthritis. The NEW INDICES study. Clin Exp Rheumatol (2010) 0.83
Managing moderate-to-severe psoriasis in the elderly. Drugs Aging (2014) 0.83
Prevalence of thyroid autoimmunity in patients with spondyloarthropathies. J Rheumatol (2011) 0.82
Role of trauma in psoriatic arthritis. J Rheumatol (2008) 0.82
Genetic epidemiology of Paget's disease of bone in italy: sequestosome1/p62 gene mutational test and haplotype analysis at 5q35 in a large representative series of sporadic and familial Italian cases of Paget's disease of bone. Calcif Tissue Int (2008) 0.82
The effectiveness of a biologic agent on axial manifestations of psoriatic arthritis. A twelve months observational study in a group of patients treated with etanercept. Clin Exp Rheumatol (2011) 0.81
Etanercept in psoriatic arthritis. J Rheumatol Suppl (2012) 0.81
Limb fat-free mass and fat mass reference values by dual-energy X-ray absorptiometry (DEXA) in a 20-80 year-old Italian population. Clin Nutr (2012) 0.81
TNF-α blockers and carotid intima-media thickness: an emerging issue in the treatment of psoriatic arthritis. Intern Emerg Med (2011) 0.81
Bilateral dexamethasone intravitreal implant in a young patient with Vogt-Koyanagi-Harada disease and refractory uveitis. Clin Rheumatol (2014) 0.80
Etanercept in spondyloarthopathies. Part II: safety and pharmacoeconomic issues. Clin Exp Rheumatol (2011) 0.80
Body mass and osteoarthritic pain: results from a study in general practice. Clin Exp Rheumatol (2013) 0.80
Hemostatic and fibrinolytic changes are related to inflammatory conditions in patients with psoriatic arthritis--effect of different treatments. J Rheumatol (2014) 0.80
Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study. Immunol Res (2015) 0.79
Etanercept in spondyloarthropathies. Part I: current evidence of efficacy. Clin Exp Rheumatol (2011) 0.79
The occurrence of lower limb enthesopathy in coeliac disease patients without clinical signs of articular involvement. Rheumatology (Oxford) (2013) 0.79